Imugene Ltd (ASX:IMU) is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors.
The company is well-funded to deliver on commercial and clinical milestones including the development of CF33, PD1-Vaxx and HER-Vaxx treatments.
